Clinical Trials
73 trialsSirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
ACTION-1
RayzeBio, Inc.
EVER-RECODE
Second Affiliated Hospital, School of Medicine, Zhejiang University
Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
Baylor Research Institute
Sapu003 in Advanced mTOR-sensitive Solid Tumors
SAPU NANO (US) LLC
COMPOSE
ITM Solucin GmbH
Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma
Captor Therapeutics S.A.
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
Novartis
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder
Banaras Hindu University
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients
Fudan University
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
ROME
Fondazione per la Medicina Personalizzata
EVIDENT
Oslo University Hospital
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
Memorial Sloan Kettering Cancer Center
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
Roswell Park Cancer Institute
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
SCRI Development Innovations, LLC
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
Washington University School of Medicine
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
Novartis
Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine
Novartis
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
Translational Oncology Research International
LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma
M.D. Anderson Cancer Center
AIO-STO-0111
Krankenhaus Nordwest
RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment
Asan Medical Center
RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX
Asan Medical Center
RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression
Asan Medical Center
Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
Hellenic Cooperative Oncology Group
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer
Swiss Cancer Institute
Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
Novartis
Gastric Cancer RAD001 Study
Chinese University of Hong Kong
Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer
Emory University
A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus
European Institute of Oncology
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
Emory University
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
EVERLAR
Grupo Espanol de Tumores Neuroendocrinos
Cancer
GlaxoSmithKline
PIE
The Queen Elizabeth Hospital
Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer
City of Hope Medical Center
TRACER
Novartis
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
University of Utah
RAD001 in Advanced Hepatocellular Carcinoma
Massachusetts General Hospital
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Mayo Clinic
Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer
Novartis
EVOLVE-1
Novartis
GITIC
Sun Yat-sen University
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
UNC Lineberger Comprehensive Cancer Center